Silvia Bianchi

Professore Associato

Università degli Studi di Torino
Country flagItaly

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Silvia Bianchi is an Associate Professor at Università degli Studi di Milano, Italy. Her research primarily focuses on infectious diseases, with recent articles addressing measles transmission dynamics, the efficacy of COVID-19 treatments, and the differential diagnosis of viral infections. Additionally, she investigates public health implications related to respiratory viruses and cancer screening methods.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

In the quest to eliminate measles virus (MV) and rubella virus (Ruv), every suspected case must be properly identified and diagnosed. Since 2017, in Milan (Italy), a total of 978 measles and rubella suspected cases (fever and rash) were investigated and 310 were not laboratory confirmed (discarded cases). To improve surveillance activities, we investigated the presence in discarded cases of 8 other viral pathogens commonly associated with rash: human herpesvirus 6 (HHV‐6) and 7 (HHV‐7), parvovirus B19 (B19V), enterovirus (EV), Epstein−Barr virus (EBV), human adenovirus (HAdV), cytomegalovirus (HCMV), and SARS‐CoV‐2. Differential diagnosis was carried out on 289 discarded cases by multiplex real‐time PCR assays. At least one pathogen was detected in 188 cases (65.1%) with HHV‐7 being the most frequently detected virus. No difference in the number of detected infections overtime was observed and infections were identified in all age groups. As expected, most HHV‐6, EV, HAdV, and HCMV‐positive cases were found in children aged 0−4 years and HHV‐7 was most frequent in the 15−39 age group. In light of the World Health Organization measles elimination goal, the introduction of laboratory methods for differential diagnosis is required for the final classification of clinically compatible cases. The used screening panel allowed us to increase the percentage of virus‐positive cases to 87.5%, allowing us to clarify viral involvement and epidemiology, improve diagnosis, and strengthen surveillance activities. As all investigated pathogens were detected, this diagnostic panel was a suitable tool to complement MV and RuV surveillance activities.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (6)

Marta Canuti

Università degli Studi di Torino

ITALY
View details

Gianvincenzo Zuccotti

University of Milan

ITALY
View details

Camilla Tincati

University of Milan

ITALY
View details

Antonella Amendola

-

ITALY
View details

Mario RAVIGLIONE

Professor

University of Milan

ITALY
View details

Maria Cristina Monti

University of Pavia

ITALY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.